{"id":534425,"date":"2021-09-03T16:08:24","date_gmt":"2021-09-03T20:08:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/"},"modified":"2021-09-03T16:08:24","modified_gmt":"2021-09-03T20:08:24","slug":"apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/","title":{"rendered":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Sept.  03, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w3GekQ7IVJL9nvQSh14eqZOFtL4oJRrX42t9ElvYrD1Sk4yrgTGd_ulgxQTlnrPXeNbRzSt5-xlqSQ2bRSQ9qHmw8-Bbt0jJvXhfW8Elma0=\" rel=\"nofollow noopener\" target=\"_blank\">Apellis Pharmaceuticals<\/a>,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to its newly appointed VP, Corporate Controller \/ Chief Accounting Officer, Jim Chopas, with a grant date of August 30, 2021, as equity inducement awards outside of the company&#8217;s 2017 Stock Incentive Plan (but under the terms of the 2021 Inducement Stock Incentive Plan) and material to Mr. Chopas entering into employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>Mr. Chopas received options to purchase 21,750 shares of Apellis common stock and 7,600 restricted stock units (RSUs). The options have an exercise price of $65.41, which is equal to the closing price of Apellis common stock on August 30, 2021, the grant date of the options. One-fourth of the shares underlying the options will vest on the one year anniversary of the grant date and thereafter 1\/48th of the shares underlying the options will vest monthly, such that the shares underlying the options will be fully vested on the fourth anniversary of the grant date, subject to Mr. Chopas\u2019 continued employment with Apellis on such vesting dates. Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to Mr. Chopas\u2019 continued employment on each vesting date.<\/p>\n<p>\n        <strong>About Apellis<\/strong><br \/>\n        <br \/>Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=761JpDNodMEyJm3gUKKhyEUQekGbNGJ1uubuzLfbFcpGTdYnFSE3_HNKanE-OP1Dhw-oDz3lI2u4tli1k3YAzw==\" rel=\"nofollow noopener\" target=\"_blank\">www.apellis.com<\/a>.<\/p>\n<p>\n        <strong>Apellis Forward-Looking Statement\u00a0<\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the \u201cRisk Factors\u201d section of Apellis\u2019 Quarterly Report on Form 10-Q filed with the\u202fSecurities and Exchange Commission\u202fon August 9, 2021\u202fand the risks described in other filings that Apellis may make with the\u202fSecurities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5vv_qGSEypg1NljLErxyvIkO2U7XnH3_3DF2G_VLOgojESJIR8-BEXXJB7kTMhr_fQZ3y5E-bxPFEYwqbSpDnXi6cDyaartdMJ5f9o2zxDo=\" rel=\"nofollow noopener\" target=\"_blank\">apellis@argotpartners.com<\/a><br \/>+1\u202f212.600.1902<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmIxYWU2YzEtZWYwZi00NjE5LWFiNzMtOWVjOTBmMzZjODk0LTEwMzE1OTg=\/tiny\/Apellis-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to its newly appointed VP, Corporate Controller \/ Chief Accounting Officer, Jim Chopas, with a grant date of August 30, 2021, as equity inducement awards outside of the company&#8217;s 2017 Stock Incentive Plan (but under the terms of the 2021 Inducement Stock Incentive Plan) and material to Mr. Chopas entering into employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Chopas received options to purchase 21,750 shares of Apellis common stock and 7,600 restricted stock units (RSUs). The options &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534425","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to its newly appointed VP, Corporate Controller \/ Chief Accounting Officer, Jim Chopas, with a grant date of August 30, 2021, as equity inducement awards outside of the company&#8217;s 2017 Stock Incentive Plan (but under the terms of the 2021 Inducement Stock Incentive Plan) and material to Mr. Chopas entering into employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Chopas received options to purchase 21,750 shares of Apellis common stock and 7,600 restricted stock units (RSUs). The options &hellip; Continue reading &quot;Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-03T20:08:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \\\/ Chief Accounting Officer\",\"datePublished\":\"2021-09-03T20:08:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/\"},\"wordCount\":511,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/\",\"name\":\"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \\\/ Chief Accounting Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=\",\"datePublished\":\"2021-09-03T20:08:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \\\/ Chief Accounting Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/","og_locale":"en_US","og_type":"article","og_title":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer - Market Newsdesk","og_description":"WALTHAM, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals,\u00a0Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to its newly appointed VP, Corporate Controller \/ Chief Accounting Officer, Jim Chopas, with a grant date of August 30, 2021, as equity inducement awards outside of the company&#8217;s 2017 Stock Incentive Plan (but under the terms of the 2021 Inducement Stock Incentive Plan) and material to Mr. Chopas entering into employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Chopas received options to purchase 21,750 shares of Apellis common stock and 7,600 restricted stock units (RSUs). The options &hellip; Continue reading \"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-03T20:08:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer","datePublished":"2021-09-03T20:08:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/"},"wordCount":511,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/","name":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=","datePublished":"2021-09-03T20:08:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTcyNSM0Mzg3NjU5IzIwMjAwMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-to-new-vp-corporate-controller-chief-accounting-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller \/ Chief Accounting Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534425"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534425\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}